The stock of Resverlogix Corp. (TSE:RVX) is a huge mover today! About 15,900 shares traded hands. Resverlogix Corp. (TSE:RVX) has risen 57.14% since March 31, 2016 and is uptrending. It has outperformed by 56.05% the S&P500.
The move comes after 7 months positive chart setup for the $245.97M company. It was reported on Nov, 4 by Barchart.com. We have $3.22 PT which if reached, will make TSE:RVX worth $142.66M more.
More notable recent Resverlogix Corp. (TSE:RVX) news were published by: Seekingalpha.com which released: “Resverlogix: RVX-208 And The Epigenetics Of Age-Related Diseases” on January 28, 2016, also Seekingalpha.com with their article: “Resverlogix: Analysis Of The Science Behind RVX-208” published on April 08, 2015, Bloomberg.com published: “Resverlogix in Discussions to Be Bought: CEO” on April 28, 2015. More interesting news about Resverlogix Corp. (TSE:RVX) were released by: Prnewswire.com and their article: “Resverlogix Names Michael Sweeney, MD, as Senior Vice President of Clinical …” published on November 03, 2014 as well as Prnewswire.com‘s news article titled: “Resverlogix Announces Annual and Special Meeting of Shareholders” with publication date: October 06, 2016.
Resverlogix Corp. is a clinical-stage biotechnology company. The company has a market cap of $245.97 million. The Firm is a development-stage company, which is engaged in developing apabetalone , a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. It currently has negative earnings. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer’s disease and orphan diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.